Compare FNWB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | ATYR |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 73.7M |
| IPO Year | 2012 | N/A |
| Metric | FNWB | ATYR |
|---|---|---|
| Price | $10.19 | $0.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $13.50 | $3.67 |
| AVG Volume (30 Days) | 63.8K | ★ 933.7K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.64 |
| 52 Week High | $10.98 | $7.29 |
| Indicator | FNWB | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 44.35 |
| Support Level | $9.26 | $0.68 |
| Resistance Level | $10.33 | $0.86 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 84.96 | 30.16 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).